Eton Pharmaceuticals Inc
ETON
查看详细走势图
16.830USD
-0.160-0.94%
收盘 12/26, 16:00（美东）报价延迟15分钟
451.34M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.94%
5天
+2.81%
1月
+3.95%
6月
+20.13%
今年开始到现在
+26.35%
1年
+28.97%
查看详细走势图
TradingKey Eton Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Eton Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名49/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价30.00。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Eton Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
30.000
目标均价
+83.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Eton Pharmaceuticals Inc亮点
亮点风险
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
业绩高增长
公司营业收入稳步增长，连续3年增长83.57%
业绩增长期
公司处于发展阶段，最新年度总收入39.01M美元
估值合理
公司最新PE估值-67.60，处于3年历史合理位
机构减仓
最新机构持股16.82M股，环比减少0.00%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.34M
活跃度降低
近期活跃度降低，过去20天平均换手率0.64
Eton Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Eton Pharmaceuticals Inc简介
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代码ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
网址https://etonpharma.com/
常见问题
Eton Pharmaceuticals Inc(ETON)的当前股价是多少？
Eton Pharmaceuticals Inc(ETON)的当前股价是 16.830。
Eton Pharmaceuticals Inc的股票代码是什么？
Eton Pharmaceuticals Inc的股票代码是ETON。
Eton Pharmaceuticals Inc股票的52周最高点是多少？
Eton Pharmaceuticals Inc股票的52周最高点是23.000。
Eton Pharmaceuticals Inc股票的52周最低点是多少？
Eton Pharmaceuticals Inc股票的52周最低点是11.087。
Eton Pharmaceuticals Inc的市值是多少？
Eton Pharmaceuticals Inc的市值是451.34M。
Eton Pharmaceuticals Inc的净利润是多少？
Eton Pharmaceuticals Inc的净利润为-3.82M。
现在Eton Pharmaceuticals Inc(ETON)的股票是买入、持有还是卖出？
根据分析师评级，Eton Pharmaceuticals Inc(ETON)的总体评级为买入，目标价格为30.000。
Eton Pharmaceuticals Inc(ETON)股票的每股收益（EPS TTM）是多少
Eton Pharmaceuticals Inc(ETON)股票的每股收益（EPS TTM）是-0.249。
相关品种
